Founded as a spin-off at the University of Málaga in 2021 by a multidisciplinary team composed of doctors, engineers and chemists, Bioherent develops integrated photonic biosensor that enable in vitro diagnosis (IVD) of allergies to beta-lactam antibiotics, such as amoxicillin or penicillin. With this tool, allergists will be able to accelerate the current clinical diagnostic practice, reducing risks to the patient and costs to the healthcare system, increasing the levels of sensitivity and specificity with respect to the current clinical standard.
Bioherent seeks to clinically validate the technology and continue internal developments to bring the product to market. This market requires biosensor-based solutions to improve the diagnostic process in terms of reliability, cost and time.
Bullnet Capital invested in Bioherent in July 2021, and has continued to support the brand ever since.